Novel Biomarker Identified for Two Different Cancers
|
By LabMedica International staff writers Posted on 17 Apr 2014 |
|
Image: Histopathology of laryngeal squamous cell carcinoma (Photo courtesy of Masaryk University).
A new biomarker linked to better outcomes for patients with head and neck cancers and non-small-cell lung cancer (NSCLC) has been identified.
The biomarker could help scientists develop new diagnostics and therapies and help physicians determine the best long-term treatments for patients with these cancers.
Scientists from the University of Pittsburgh (PA, USA) examined tumor samples from 187 patients with non-small-cell lung cancer and 60 patients with head and neck squamous cell carcinomas (HNSCC). The median follow-up for overall survival (OS) and disease-free survival (DFS) for NSCLC patients was 69.0 months and 35.9 months, respectively. The median follow-up for HNSCC patients was 41 months.
The team used antibody-based immunological techniques, cell cultures, immunoprecipitation, immunohistochemistry and in situ quantification. For tumor analysis, tissue microarrays of formalin-fixed and paraffin-embedded tumors and control tissues were used. Each tumor was represented by three distinct cores for NSCLC and two for HNSCC. The nuclear signal intensity was quantified by automated quantitative analysis for NSCLC and Aperio software for HNSCC (Aperio Technologies, Vista, CA, USA).
The investigators found that the expression of a protein called choline phosphate cytidylyltransferase-α CCT-α or CCTα, which acts as an “antigen” that prompts the immune system to produce antibodies against it. CCTα was associated with longer survival rates, including for patients with NSCLC who were treated with surgery alone, without the use of platinum-based chemotherapy drugs and associated toxic side effects.
Laura J. Niedernhofer, MD, PhD, an associate professor and a senior author of the study said, “Based on what we found, a high CCTα expression appears to be indicative of survival, making CCTα a promising biomarker. Our findings suggest that CCTα may, in fact, be more important in determining outcomes in patients with both types of cancer than the already established excision repair cross-complementation group 1 (ERCC1) protein.”
Related Links:
University of Pittsburgh
Aperio Technologies
The biomarker could help scientists develop new diagnostics and therapies and help physicians determine the best long-term treatments for patients with these cancers.
Scientists from the University of Pittsburgh (PA, USA) examined tumor samples from 187 patients with non-small-cell lung cancer and 60 patients with head and neck squamous cell carcinomas (HNSCC). The median follow-up for overall survival (OS) and disease-free survival (DFS) for NSCLC patients was 69.0 months and 35.9 months, respectively. The median follow-up for HNSCC patients was 41 months.
The team used antibody-based immunological techniques, cell cultures, immunoprecipitation, immunohistochemistry and in situ quantification. For tumor analysis, tissue microarrays of formalin-fixed and paraffin-embedded tumors and control tissues were used. Each tumor was represented by three distinct cores for NSCLC and two for HNSCC. The nuclear signal intensity was quantified by automated quantitative analysis for NSCLC and Aperio software for HNSCC (Aperio Technologies, Vista, CA, USA).
The investigators found that the expression of a protein called choline phosphate cytidylyltransferase-α CCT-α or CCTα, which acts as an “antigen” that prompts the immune system to produce antibodies against it. CCTα was associated with longer survival rates, including for patients with NSCLC who were treated with surgery alone, without the use of platinum-based chemotherapy drugs and associated toxic side effects.
Laura J. Niedernhofer, MD, PhD, an associate professor and a senior author of the study said, “Based on what we found, a high CCTα expression appears to be indicative of survival, making CCTα a promising biomarker. Our findings suggest that CCTα may, in fact, be more important in determining outcomes in patients with both types of cancer than the already established excision repair cross-complementation group 1 (ERCC1) protein.”
Related Links:
University of Pittsburgh
Aperio Technologies
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Laboratory Software
ArtelWare
Homocysteine Quality Control
Liquichek Homocysteine Control
Latest Pathology News
- Deep Learning–Based Method Improves Cancer Diagnosis
- ADLM Updates Expert Guidance on Urine Drug Testing for Patients in Emergency Departments
- New Age-Based Blood Test Thresholds to Catch Ovarian Cancer Earlier
- Genetics and AI Improve Diagnosis of Aortic Stenosis
- AI Tool Simultaneously Identifies Genetic Mutations and Disease Type
- Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups
- Tumor Signals in Saliva and Blood Enable Non-Invasive Monitoring of Head and Neck Cancer
- Common Health Issues Can Influence New Blood Tests for Alzheimer’s Disease
- Blood Test Formula Identifies Chronic Liver Disease Patients with Higher Cancer Risk
- Tunable Cell-Sorting Device Holds Potential for Multiple Biomedical Applications
- AI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
- AI Tool Rapidly Analyzes Complex Cancer Images for Personalized Treatment
- Diagnostic Technology Performs Rapid Biofluid Analysis Using Single Droplet
- Novel Technology Tracks Hidden Cancer Cells Faster
- AI Tool Improves Breast Cancer Detection
- AI Tool Predicts Treatment Success in Rectal Cancer Patients
Channels
Clinical Chemistry
view channel
Blood Test Could Predict and Identify Early Relapses in Myeloma Patients
Multiple myeloma is an incurable cancer of the bone marrow, and while many patients now live for more than a decade after diagnosis, a significant proportion relapse much earlier with poor outcomes.... Read more
Compact Raman Imaging System Detects Subtle Tumor Signals
Accurate cancer diagnosis often depends on labor-intensive tissue staining and expert pathological review, which can delay results and limit access to rapid screening. These conventional methods also make... Read more
Molecular Diagnostics
view channel
Sepsis Test Demonstrates Strong Performance in Post-Cardiac Surgery Patients
Sepsis is difficult to diagnose accurately in patients recovering from major surgery, as infection-related symptoms often overlap with non-infectious systemic inflammatory responses. This challenge is... Read more
Next-Gen Automated ELISA System Elevates Laboratory Performance
A next-generation automated ELISA system is designed to elevate laboratory performance through advanced workflow automation, enhanced connectivity, and a modernized user experience. DYNEX Technologies... Read more
At-Home Blood Tests Accurately Detect Key Alzheimer's Biomarkers
Diagnosing Alzheimer’s disease typically relies on brain scans or spinal fluid tests, which are invasive, costly, and difficult to access outside specialist clinics. These barriers have limited large-scale... Read more
Blood Test Combined with MRI Brain Scans Reveals Two Distinct Multiple Sclerosis Types
Multiple sclerosis (MS) affects more than 2.8 million people worldwide, yet predicting how the disease will progress in individual patients remains difficult. Current MS classifications are based on clinical... Read moreHematology
view channel
MRD Tests Could Predict Survival in Leukemia Patients
Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreMicrobiology
view channel
New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
Urinary tract infections affect around 152 million people every year, making them one of the most common bacterial infections worldwide. In routine medical practice, diagnosis often relies on rapid urine... Read more
Breakthroughs in Microbial Analysis to Enhance Disease Prediction
Microorganisms shape human health, ecosystems, and the planet’s climate, yet identifying them and understanding how they are related remains a major scientific challenge. Even with modern DNA sequencing,... Read more
Pathology
view channel
Deep Learning–Based Method Improves Cancer Diagnosis
Identifying vascular invasion is critical for determining how aggressive a cancer is, yet doing so reliably can be difficult using standard pathology workflows. Conventional methods require multiple chemical... Read more
ADLM Updates Expert Guidance on Urine Drug Testing for Patients in Emergency Departments
Urine drug testing plays a critical role in the emergency department, particularly for patients presenting with suspected overdose or altered mental status. Accurate and timely results can directly influence... Read more
Technology
view channel
Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
Detecting cancer early and tracking how it responds to treatment remains a major challenge, particularly when cancer cells are present in extremely low numbers in the bloodstream. Circulating tumor cells... Read more
AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
Colorectal cancer is one of the most common and deadly cancers worldwide, and accurately predicting patient survival remains a major clinical challenge. Traditional prognostic tools often rely on either... Read more
Industry
view channel
WHX Labs Dubai to Gather Global Experts in Antimicrobial Resistance at Inaugural AMR Leaders’ Summit
World Health Expo (WHX) Labs in Dubai (formerly Medlab Middle East), which will be held at Dubai World Trade Centre from 10-13 February, will address the growing global threat of antimicrobial resistance... Read more
